Back
#1
23.5%
Top 2%
6.8%
#1
6.8%
Top 15%
6.8%
Top 0.4%
6.3%
Top 54%
5.3%
Top 85%
4.1%
Top 10%
4.1%
Top 4%
2.1%
Top 0.1%
2.1%
Top 0.7%
1.6%
Top 6%
1.4%
Top 8%
1.4%
Top 4%
1.2%
Top 7%
1.2%
Top 7%
1.0%
Top 0.2%
1.0%
Top 11%
1.0%
Top 18%
1.0%
Top 8%
0.8%
Top 4%
0.8%
TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
2025-11-19
hematology
Title + abstract only
View on medRxiv
Show abstract
Occasional complete responses to immune checkpoint inhibitor therapies suggest that acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are immune-sensitive when appropriately targeted. Here, we analyzed AML/MDS patients treated with anti-TIM3 sabatolimab and decitabine in a phase Ib clinical trial (NCT03066648) using single-cell RNA and T cell receptor (TCR) sequencing and functional co-culture assays. Unlike T cell restricted CTLA4 and PD1, TIM3 was broadly expressed across natural...
Predicted journal destinations
1
Blood Advances
16 training papers
2
Frontiers in Immunology
140 training papers
3
Journal of Clinical Investigation
50 training papers
4
Nature Communications
483 training papers
5
JCI Insight
63 training papers
6
Scientific Reports
701 training papers
7
PLOS ONE
1737 training papers
8
eLife
262 training papers
9
Proceedings of the National Academy of Sciences
100 training papers
10
Science Advances
52 training papers
11
Cell
28 training papers
12
Cancers
57 training papers
13
Nature Genetics
72 training papers
14
Cell Reports Medicine
49 training papers
15
iScience
74 training papers
16
Nature
58 training papers
17
JAMA
17 training papers
18
Nature Medicine
88 training papers
19
Frontiers in Medicine
99 training papers
20
The American Journal of Human Genetics
77 training papers
21
Science Translational Medicine
40 training papers